Skip to Main Content

Author Details

Michelle H Braccioforte
Prostate Cancer Foundation of Chicago
2006
38
18
PMIDPaper TitleJournal TitlePublished Year
34315661The risk of death from prostate cancer in men with Gleason score 3+4 prostate cancer treated using brachytherapy with or without a short course of androgen deprivation therapy.Urol Oncol2022
33059997Long-term outcomes of a prospective randomized trial of <sup>131</sup>Cs/<sup>125</sup>I permanent prostate brachytherapy.Brachytherapy2021
33985797Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.Eur Urol2021
34196715Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.JAMA Netw Open2021
30452521Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.JAMA Oncol2019
31427178Long-term biochemical outcomes using cesium-131 in prostate brachytherapy.Brachytherapy2019
28753752Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOT.Eur Urol Focus2018
30143400Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.Brachytherapy2018
29276060Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer.Urol Oncol2018
27209511Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy Alone.Int J Radiat Oncol Biol Phys2016
26388503Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death.Eur Urol2016
27788950Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.Int J Radiat Oncol Biol Phys2016
27490845Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.Cancer2016
25124891Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.BJU Int2015
26361718Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy.Brachytherapy2015
26530751Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.Int J Radiat Oncol Biol Phys2015
26181182Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.JAMA Oncol2015
25925789Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.Cancer2015
22981136Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.Eur Urol2014
23332383Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy.Int J Radiat Oncol Biol Phys2013
21708431Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.Int J Radiat Oncol Biol Phys2012
22130293Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.Clin Genitourin Cancer2012
21944463Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer.Int J Radiat Oncol Biol Phys2012
20605366Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size.Int J Radiat Oncol Biol Phys2011
22019035Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy.J Urol2011
21571341Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.J Urol2011
21349778Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice.Brachytherapy2011
19540066Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.Int J Radiat Oncol Biol Phys2010
20556875Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease.Alzheimer Dis Assoc Disord2010
20230380Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke.BJU Int2010
20310055Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.Cancer2010
20346894The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement.Brachytherapy2010
19879061Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer.Int J Radiat Oncol Biol Phys2010
19744800Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.Int J Radiat Oncol Biol Phys2010
19027936Stereotactic transperineal prostate biopsy.Urology2009
19597029Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease.J Clin Oncol2009
19706860Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.JAMA2009
16952636Re-biopsy of the prostate using a stereotactic transperineal technique.J Urol2006
  • 1 - 38 of 38

Recommended Authors

Sebastiaan Remmers
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 2018
Number of shared co-authors 1
Chenyang Wang
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Career Start Year 2017
Number of shared co-authors 15
Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 13
Adam B Weiner
Northwestern University Feinberg School of Medicine
Career Start Year 2013
Number of shared co-authors 18
William C Jackson
University of Michigan ann arbor
Career Start Year 2013
Number of shared co-authors 35
Giorgio Gandaglia
IRCCS San Raffaele Scientific Institute, Italy Vita-Salute San Raffaele University
Career Start Year 2012
Number of shared co-authors 24
Francesco Pellegrino
Urological Research Institute, IRCCS San Raffaele Hospital
Career Start Year 2012
Number of shared co-authors 2
Nicholas G Zaorsky
University Hospitals Seidman Cancer Centre, Cleveland Medical Centre
Career Start Year 2012
Number of shared co-authors 59
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 12
Ting Martin Ma
University of Washington
Career Start Year 2010
Number of shared co-authors 58
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 3
Bridget F Koontz
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 18
Nima Aghdam
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 18
Himanshu Nagar
New York-Presbyterian Hospital, Weill Cornell Medical Center
Career Start Year 2005
Number of shared co-authors 11
Alberto Briganti
IRCCS San Raffaele Scientific Institute
Career Start Year 2002
Number of shared co-authors 30
Piet Ost
Ghent University, GZA Ziekenhuizen
Career Start Year 2002
Number of shared co-authors 25
Andrew K Lee
Texas Center for Proton Therapy
Career Start Year 2001
Number of shared co-authors 3
Mark K Buyyounouski
Stanford University
Career Start Year 1999
Number of shared co-authors 25
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 27
Vincent J Gnanapragasam
University of Cambridge
Career Start Year 1999
Number of shared co-authors 2
Stephen J Freedland
Cedars-Sinai Medical Center
Career Start Year 1996
Number of shared co-authors 33
Simeng Suy
MedStar Georgetown University Hospital
Career Start Year 1996
Number of shared co-authors 19
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 8
Andrew Loblaw
Princess Margaret Hospital, University of Toronto
Career Start Year 1995
Number of shared co-authors 17
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 17
Neil E Fleshner
University of Toronto
Career Start Year 1989
Number of shared co-authors 15
Christopher R King
University of California los angeles
Career Start Year 1988
Number of shared co-authors 41
Mark Frydenberg
Monash University
Career Start Year 1988
Number of shared co-authors 11
Mack Roach
University of California San Francisco
Career Start Year 1983
Number of shared co-authors 37
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1976
Number of shared co-authors 36

Collaborators

Brian J Moran
Chicago Prostate Cancer Center
Co-authored papers 38
Anthony V D'Amico
Duke University Medical Center
Co-authored papers 31
Ming-Hui Chen
Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School
Co-authored papers 31
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Co-authored papers 6
Toni K Choueiri
Dana-Farber Cancer Institute
Co-authored papers 5
Derya Tilki
Universitatsklinikum Hamburg-Eppendorf
Co-authored papers 3
Jim C Hu
Weill Cornell Medical Center
Co-authored papers 3
Jay P Ciezki
Cleveland Clinic
Co-authored papers 2
Brian J Davis
Mayo Clinic
Co-authored papers 2
Jeffrey J Tosoian
Vanderbilt University Medical Center
Co-authored papers 2
Todd McNutt
Johns Hopkins University School of Medicine
Co-authored papers 2
Rahul D Tendulkar
Taussig Cancer Institute, Cleveland Clinic
Co-authored papers 2
Eyad Abu-Isa
Ascension Providence Hospital
Co-authored papers 2
Robert T Dess
University of Michigan ann arbor
Co-authored papers 2
Michael L Steinberg
University of California los angeles
Co-authored papers 2
Curtiland Deville
Johns Hopkins University
Co-authored papers 2
Amar U Kishan
University of California los angeles
Co-authored papers 2
David Elashoff
David Geffen School of Medicine at University of California los angeles
Co-authored papers 2
Patrick A Kupelian
university of california los angeles Medical Center
Co-authored papers 2
David Shabsovich
university of california los angeles Medical Center
Co-authored papers 2
Eric M Horwitz
Fox Chase Cancer Center
Co-authored papers 2
Hartwig Huland
Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf
Co-authored papers 2
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 2
Tahmineh Romero
David Geffen School of Medicine at university of california los angeles
Co-authored papers 2
David Jeffrey Demanes
University of California los angeles
Co-authored papers 2
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 2
Trude B Wedde
Oslo University Hospital
Co-authored papers 2
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 2
Chandana A Reddy
Cleveland Clinic
Co-authored papers 2
Avinash Pilar
Princess Margaret Cancer Centre, University of Toronto
Co-authored papers 2
Release 1.2